The FDA’s once-raging internal debate over Sarepta Therapeutics (SRPT) has cooled, but a recently unearthed document might portend failure for the next company angling to win an approval in Duchenne muscular dystrophy.
PTC Therapeutics (PTCT) is seeking approval for its treatment, ataluren, despite the drug’s repeated clinical failures and the FDA’s 2016 refusal to even consider the drug. Approval would seem unlikely, and it looks to be even more of a reach in light of a memo written by Dr. John Jenkins, an FDA official, back in the heat of the Sarepta saga.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
This statement is not true it only says beware of all bio pharma companies not just for ptct fda does not hint in anything here restate
It was always nice to read articles by Adam now not accessible. So awesome of stat to be greedy and help promoters and fraudsters by hiding the truth. These stories were free at the street.